Literature DB >> 10792988

HTLV-1 tax oncoprotein binds to DNA topoisomerase I and inhibits its catalytic activity.

T Suzuki1, M Uchida-Toita, T Andoh, M Yoshida.   

Abstract

HTLV-1 Tax oncoprotein exerts pleiotropic effects on cellular regulatory systems, such as transcription and the cell cycle, through the interaction with various cellular factors. During our search for additional cellular targets of Tax using a yeast two-hybrid screening system, we isolated a cDNA encoding human DNA topoisomerase I. Tax was demonstrated to bind to topoisomerase I in vitro, and the Tax-topoisomerase I complex was also detected in HTLV-1-infected T-cells by immunoprecipitation. Furthermore, Tax inhibited the catalytic activity of topoisomerase I as measured by relaxation of supercoiled DNA, although complete inhibition was not observed under the conditions used. The binding of topoisomerase I to DNA was inhibited by the addition of the wild type of Tax but not by a mutant of Tax that cannot bind to topoisomerase I. Consistent with these observations, expression of Tax induced an in vivo reduction of the covalent association of topoisomerase I with chromosomal DNA, which accumulates in the presence of camptothecin. These results suggest that Tax has a novel potential to affect various cellular processes such as transcription and maintenance of genomic stability, in which DNA topoisomerase I is involved. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792988     DOI: 10.1006/viro.2000.0266

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Human T-lymphotropic type 1 virus p30 inhibits homologous recombination and favors unfaithful DNA repair.

Authors:  Hicham H Baydoun; Joanna Pancewicz; Christophe Nicot
Journal:  Blood       Date:  2011-03-22       Impact factor: 22.113

2.  Transcriptional consequences of topoisomerase inhibition.

Authors:  I Collins; A Weber; D Levens
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 3.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 4.  HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches.

Authors:  John M Taylor; Christophe Nicot
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

5.  Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 tax oncoproteins modulate cell cycle progression and apoptosis.

Authors:  Michelle Sieburg; Adam Tripp; Jung-Woo Ma; Gerold Feuer
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 6.  Molecular approach to human leukemia: isolation and characterization of the first human retrovirus HTLV-1 and its impact on tumorigenesis in adult T-cell leukemia.

Authors:  Mitsuaki Yoshida
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

Review 7.  The HTLV-1 Tax interactome.

Authors:  Mathieu Boxus; Jean-Claude Twizere; Sébastien Legros; Jean-François Dewulf; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2008-08-14       Impact factor: 4.602

8.  Characterization of BTBD1 and BTBD2, two similar BTB-domain-containing Kelch-like proteins that interact with Topoisomerase I.

Authors:  Lixin Xu; Lihong Yang; Keiko Hashimoto; Melvin Anderson; Glenda Kohlhagen; Yves Pommier; Peter D'Arpa
Journal:  BMC Genomics       Date:  2002-01-07       Impact factor: 3.969

9.  HTLV-I tax increases genetic instability by inducing DNA double strand breaks during DNA replication and switching repair to NHEJ.

Authors:  Hicham H Baydoun; Xue Tao Bai; Shary Shelton; Christophe Nicot
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

Review 10.  Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity.

Authors:  Inbal Azran; Yana Schavinsky-Khrapunsky; Mordechai Aboud
Journal:  Retrovirology       Date:  2004-08-13       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.